Heidelberg Pharma AG Stock
Price
Target price
€2.96
€2.96
4.960%
0.14
4.960%
-
19:42 / Tradegate
WKN: A11QVV / Name: Heidelberg Pharma / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Heidelberg Pharma AG Stock
Heidelberg Pharma AG dominated the market today, gaining €0.14 (4.960%).
So far the community has only identified positive things for Heidelberg Pharma AG stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Heidelberg Pharma AG in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
S********** s********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Heidelberg Pharma AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Heidelberg Pharma AG | 4.960% | -5.369% | -9.032% | 1.805% | 17.012% | -35.023% | -63.472% |
| Vivoryon Therapeutics N.V. | 1.530% | 1.550% | -5.347% | -25.653% | -9.405% | -90.696% | -91.393% |
| Nanorepro AG | 6.500% | 0.362% | -10.065% | -4.483% | -7.973% | -28.052% | -90.315% |
| Northwest Biotherapeutics Inc. | -2.780% | 5.882% | -14.286% | 0.000% | -12.621% | -66.355% | -85.000% |
Comments
systinvest bought the security Heidelberg Pharma AG in his wikifolio Aktienwertselektion mit System.
Show more
News
EQS-News: Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026
EQS-News: Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026
EQS-News: Heidelberg Pharma Announces Financial Figures and Reports on Business Performance in 2025 and Outlook for 2026
EQS-News: Heidelberg Pharma Announces Financial Figures and Reports on Business Performance in 2025 and Outlook for 2026
EQS-News: Heidelberg Pharma to Receive Milestone Payment from Partner Huadong for Clinical Study with HDP-101 in China
EQS-News: Heidelberg Pharma to Receive Milestone Payment from Partner Huadong for Clinical Study with HDP-101 in China